Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics

DOI HANDLE PubMed オープンアクセス

説明

<jats:p>Allosteric modulation of G protein-coupled receptors (GPCRs) is a major paradigm in drug discovery. Despite decades of research, a molecular-level understanding of the general principles that govern the myriad pharmacological effects exerted by GPCR allosteric modulators remains limited. The M<jats:sub>4</jats:sub> muscarinic acetylcholine receptor (M<jats:sub>4</jats:sub> mAChR) is a validated and clinically relevant allosteric drug target for several major psychiatric and cognitive disorders. In this study, we rigorously quantified the affinity, efficacy, and magnitude of modulation of two different positive allosteric modulators, LY2033298 (LY298) and VU0467154 (VU154), combined with the endogenous agonist acetylcholine (ACh) or the high-affinity agonist iperoxo (Ipx), at the human M<jats:sub>4</jats:sub> mAChR. By determining the cryo-electron microscopy structures of the M<jats:sub>4</jats:sub> mAChR, bound to a cognate G<jats:sub>i1</jats:sub> protein and in complex with ACh, Ipx, LY298-Ipx, and VU154-Ipx, and applying molecular dynamics simulations, we determine key molecular mechanisms underlying allosteric pharmacology. In addition to delineating the contribution of spatially distinct binding sites on observed pharmacology, our findings also revealed a vital role for orthosteric and allosteric ligand–receptor–transducer complex stability, mediated by conformational dynamics between these sites, in the ultimate determination of affinity, efficacy, cooperativity, probe dependence, and species variability. There results provide a holistic framework for further GPCR mechanistic studies and can aid in the discovery and design of future allosteric drugs.</jats:p>

収録刊行物

  • eLife

    eLife 12 2023-05-30

    eLife Sciences Publications, Ltd

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ